Navigation Links
Imagenetix, Inc. Reports Second Quarter 2011 Results
Date:11/16/2010

ceutical products developed to enhance human health on a global basis.  Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution.  In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners.  Imagenetix is the creator of Celadrin®.  Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected.  Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services.  Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.Contact Imagenetix Investor Relations

William P. Spencer(858)385-2797

Chief Executive OfficerImagenetix, Inc.Tel: (858) 674-8455Imagenetix, Inc.Condensed Consolidated Statements of Operations(Unaudited)

(In thousands, except per share data)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009Net sales$

3,220$

1,901$

4,305$

3,603   Cost of sales1,4321,0392,1822,095Gross profit1,7888622,1231,508Gross profit percent55.5%45.3%49.3%41.9%Operating expenses:Genera
'/>"/>

SOURCE Imagenetix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Imagenetix, Inc. Reports First Quarter 2011 Results
2. Imagenetix, Inc. to Present at the 2009 RedChip New York Equities Conference
3. Imagenetix, Inc. Announces Interview With Bloomberg Radio
4. Imagenetix, Inc. Reports First Quarter 2010 Results
5. Imagenetix, Inc. Reports Second Quarter and Six Month Results
6. Transgenomic Reports Third Quarter Financial Results
7. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
9. Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
10. Dyadic International Reports 2010 Third Quarter Financial Results
11. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013   ... the development of disease modifying therapeutics for Alzheimer,s ... the completion of its Series B financing, which ... and warrants that would represent approximately $2.8M in ... and new investors supported the raise. ...
(Date:5/22/2013)... 22, 2013  Superior Controls, Inc. has been ... Business NH Magazine.  For the past 22 years, ... distinguish themselves with extraordinary business and civic excellence. ... this honor," said Rick Pierro ... recognition, this award is a reflection of Superior ...
(Date:5/22/2013)... Switzerland (PRWEB) May 22, 2013 ... for industrial biotechnology, drug discovery, and life science ... Genedata Selector ™ as its bioinformatics platform ... production-relevant organisms. Genedata will provide AB Enzymes, one ... with a hosted solution of Genedata Selector accompanied ...
(Date:5/22/2013)... Ontario (PRWEB) May 22, 2013 ... advanced sound therapy for tinnitus treatment. AudioNotch is ... Hearing . With clinic locations in both British ... provider of audiology and hearing services. AudioNotch's tinnitus ... locations. , Upon entering a Destination Hearing clinic, ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2
... of Investment Success -, GAITHERSBURG, Md., Jan. ... of AstraZeneca plc (LSE: AZN.L, NYSE:,AZN), today announced ... will broaden its focus to include areas of ... areas of,cardiovascular and metabolic disease, pain and central ...
... 7 Boston Scientific,Corporation (NYSE: BSX ) today ... Surgery and Vascular Surgery businesses to the Getinge Group ... the definitive agreement,announced on November 5, 2007., The ... in connection with the transaction. These charges will be ...
... MONICA, Calif., Jan. 7 Aida,Pharmaceuticals, Inc. (OTC ... an award from the Science and Technology Department ... China and known throughout,the country for its focus ... because of its "clinical research and,commercialization of Rh-Apo2L" ...
Cached Biology Technology:MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 3Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses 2Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses 3Aida Receives Chinese Government Innovation Award 2
(Date:5/22/2013)... in a major new effort to educate the public ... people with clean water that looms ahead in the ... in the current edition of Chemical & Engineering ... Society (ACS), the world,s largest scientific society. , Bassam ... L. Schnoor, Ph.D., explain that shortages of reliable supplies ...
(Date:5/22/2013)... bacteria is responsible for legionellosis, an infectious disease that ... this pathogen has developed a complex method enabling it ... thus avoiding these acting against the infectious bacteria. , ... bioGUNE, in which teams from the National Institute of ... Centre in Barcelona (BSC) have also participated, has described ...
(Date:5/21/2013)... known for a long time that some creatures evolve ... particularly for plants. But it may be that height ... University and the U. S. National Evolutionary Synthesis Center. ... May in the journal Nature Communications , Lanfear ... , Drawing from a database of global patterns in ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Small but speedy: Short plants live in the evolutionary fast lane 2
... Max Delbrck Center for Molecular Medicine (MDC) Berlin is to ... Prize. The announcement was made by the German Research Foundation ... time the prize will go to the MDC. In 2002 ... will be awarded to a total of eleven scientists: two ...
... mouse model to investigate allergy to fenugreek has been developed ... study cross-reactivity to peanut, soy and lupin, major food allergens ... of the legume family and is used as an ingredient ... be severe yet its presence is rarely declared in ingredient ...
... that are twisted are ubiquitous in nature, and have important ... have unique and technologically useful optical properties; the medicinal properties ... within us think of the double helix twisted ... is called chirality and researchers at Case Western Reserve University ...
Cached Biology News:Nikolaus Rajewsky of the MDC to receive the Leibniz Prize 2New food allergy model for fenugreek developed 2Twisting molecules by brute force: A top-down approach 2Twisting molecules by brute force: A top-down approach 3
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
...
EMBP (FL-222)...
Rabbit anti-T-box 6...
Biology Products: